Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (322) clinical trials

Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

The phase 1b portion of the trial is a radiation dose escalation study to determine the maximum tolerated dose (MTD) of SBRT when given to patients previously and subsequently exposed to MK-3475. Because the class of PD-1 inhibitory antibodies conveys a risk of pneumonitis, there will be two parallel dose ...

Phase

Improving Goals of Care Discussion in Advanced Cancer Patients

Among advanced cancer patients, discussions about prognosis, goals of care (GoC) and end-of-life preferences improve quality of life of patients and reduce rates of hospital and ICU admission. Yet, few patients know their chemotherapy treatments will not cure their disease despite nearly all wishing to receive information- good & bad. ...

Phase N/A

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Tumor hypoxia can lead to poor effector T cell penetration and immunosuppressive signaling via myeloid-derived suppressor, myofibroblast and regulatory T cells. Disruption of these hypoxic regions within the tumor microenvironment by the hypoxia-directed cytotoxic agent evofosfamide may enhance the ability of the CTLA-4 checkpoint inhibitor ipilimumab to reject otherwise resistant ...

Phase

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

The study will enrol adult female and male patients with BRAF wild-type melanoma and brain metastases who are not eligible for surgery or radiosurgery and failed prior therapy with ipilimumab, and patients with BRAF V600 mutation-positive melanoma and brain metastases who are not eligible for surgery or radiosurgery and who ...

Phase

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

By enrolling patients with small metastases of melanoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according ...

Phase

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

This is a Phase I/II study. Phase I will be evaluating the safety of the FDA-approved Vemurafenib (960 mg orally, daily) in combination with Metformin (500 mg orally, twice daily for 2 weeks, then 850 mg orally,twice daily) in patients with unresectable Stage IIIC and Stage IV melanoma. Phase II ...

Phase

Neoadjuvant L19IL2/L19TNF- Pivotal Study

Phase III, open-label, randomized, controlled multi-center study. In the study, 214 patients will be enrolled and parallel assigned (via randomization system) in a 1:1 fashion to one of two different arms: ARM 1: Patients in Arm 1 will receive multiple intratumoral administrations into all injectable cutaneous, subcutaneous, and nodal tumors ...

Phase

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study

Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized "proof-of-principle" phase II study. Short Title/Acronym: ABSIDE (ABScopal effect-Interferon alpha-DEndritic cells) Protocol Code IRST172.02 Phase: phase II clinical trial Study Design: Randomized selection ...

Phase

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

Each tumour will be assessed by itself. Regorafenib 40 mg tablets will be used in the study. Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least ...

Phase

Study to Assess Safety and Tolerability of Intranodal ECI-006 in Melanoma Patients With no Evidence of Disease

The purpose of this study is to assess the safety and tolerability of cancer immunotherapy ECI-006 and to determine its ability to induce a measurable immune response against the tumor associated antigens. ECI-006 will be administered 5 times by injection in a lymph node in the groin or armpit. ECI-006 ...

Phase